InsightfulValue
← Home

Santen Pharmaceutical
Santen Pharmaceutical

Pharma / Ophthalmic pharmaceuticals and eye care


πŸ”§ Tools

βœ… Due Diligence
Company at a Glance

Santen Pharmaceutical

πŸ“Š Get full analytics about Santen Pharmaceutical

Sign up for free or log in

πŸ”“ Unlock our free guide: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

Price
Live  
Overview
Santen Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company specializing in ophthalmic treatments. The company was founded in 1890 and is headquartered in Osaka, Japan. Santen focuses on developing, producing and marketing prescription ophthalmic products, over-the-counter eye drops, and medical devices.
History and milestones
Santen was originally founded in 1890 as Kobe Santa Corporation, a wholesaler of Western medicines. In 1917, the company changed its name to Santen Pharmaceutical Co., Ltd. and shifted its focus to ophthalmology.
Throughout the 20th century, Santen developed and marketed various ophthalmic treatments, including solutions for cataracts, dry eye syndrome, glaucoma, and others. In the 1960s and 1970s, the company expanded its global presence, establishing subsidiaries and joint ventures in Europe, North America, and Asia.
In the 1980s, Santen began developing and manufacturing intraocular lenses for cataract surgery. In 1989, the company opened a research and development center in Tsukuba, Japan, to further its innovative treatments and medical devices.
In recent years, Santen has continued to expand its portfolio and global presence through acquisitions and partnerships. In 2010, the company acquired the U.S.-based company, ISTA Pharmaceuticals, to further its presence in the U.S. In 2011, Santen acquired the Japanese company, Ophthalmics Inc., and in 2014, the company established a joint venture with GlaxoSmithKline to develop and commercialize innovative ophthalmic products.
Products and Sectors
Santen specializes in prescription ophthalmic products, over-the-counter eye drops, and medical devices for various eye conditions. The company has a wide portfolio of products targeting various eye diseases, including dry eye syndrome, glaucoma, cataracts, and retinal disorders.
Santen’s key products include Ikervis, a prescription eye drop for the treatment of severe dry eye in Europe and other countries, and Taflotan, a prescription eye drop for the treatment of glaucoma in Europe and Asia.
In addition to pharmaceutical treatments, Santen also produces medical devices, including intraocular lenses, surgical instruments, and diagnostic equipment for cataracts and other eye conditions.
Research and Development
Santen invests a significant portion of its revenue into research and development (R&D). The company has established research facilities in Japan, the U.S., Europe, and China to develop innovative treatments for eye diseases. With over 1,600 employees dedicated to R&D, Santen’s efforts have led to the development of numerous innovative treatments and medical devices.
Sustainability
Santen is committed to sustainability and corporate social responsibility. The company has established initiatives to reduce its environmental impact, promote diversity and inclusion, and contribute to the community through various programs and partnerships.
In 2019, Santen joined the United Nations Global Compact, the world’s largest corporate sustainability initiative, and pledged to align its operations with the Ten Principles of the UN Global Compact in the areas of human rights, labor, environment, and anti-corruption.
Conclusion
Santen Pharmaceutical Co., Ltd. is a leading ophthalmic-focused pharmaceutical company with a long history of developing innovative treatments and medical devices for eye diseases. Through its commitment to R&D and sustainability, Santen remains dedicated to improving the lives of those suffering from eye conditions globally.
What is special about the company?
Santen Pharmaceutical

πŸ“ˆ Want to read more about Santen Pharmaceutical?

Sign up for free or log in

πŸ“˜ Claim your free eBook: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

VGhlcmUgYX JlIGEgZmV3 IHVuaXF1ZS Bhc3BlY3Rz IHRoYXQgc2 V0IHRoZSBT YW50ZW4gUG hhcm1hY2V1 dGljYWwgY2 9tcGFueSBh cGFydCBmcm 9tIG90aGVy IHBoYXJtYW NldXRpY2Fs IGNvbXBhbm llczogPGJy PjEuIEZvY3 VzIG9uIE9w aHRoYWxtb2 xvZ3k6IFNh bnRlbiBzcG VjaWFsaXpl cyBpbiBwaG FybWFjZXV0 aWNhbHMgYW 5kIG1lZGlj YWwgZGV2aW NlcyBmb3Ig b3BodGhhbG 1pYyBkaXNl YXNlcyBhbm QgY29uZGl0 aW9ucy4gVG hpcyBmb2N1 c2VkIGFwcH JvYWNoIGFs bG93cyB0aG VtIHRvIGJl IGFuIGV4cG VydCBpbiBl eWUgaGVhbH RoIGFuZCBw cm92aWRlIG lubm92YXRp dmUgdHJlYX RtZW50cyBm b3IgcGF0aW VudHMgd2l0 aCBleWUgZG lzZWFzZXMg YW5kIGRpc2 9yZGVycy4g PGJyPjIuIE dsb2JhbCBQ cmVzZW5jZT ogU2FudGVu IGlzIGEgZ2 xvYmFsIGNv bXBhbnkgd2 l0aCBhIHN0 cm9uZyBwcm VzZW5jZSBp biBBc2lhLC BFdXJvcGUs IGFuZCB0aG UgVW5pdGVk IFN0YXRlcy 4gVGhpcyBh bGxvd3MgdG hlbSB0byBy ZWFjaCBhIH dpZGVyIG1h cmtldCBhbm QgcHJvdmlk ZSB0aGVpci Bwcm9kdWN0 cyB0byBhIG RpdmVyc2Ug cmFuZ2Ugb2 YgcGF0aWVu dHMgd29ybG R3aWRlLiA8 YnI+My4gQ2 9tbWl0bWVu dCB0byBSZX NlYXJjaCBh bmQgRGV2ZW xvcG1lbnQ6 IFNhbnRlbi BpbnZlc3Rz IGhlYXZpbH kgaW4gcmVz ZWFyY2ggYW 5kIGRldmVs b3BtZW50LC B3aXRoIGEg Zm9jdXMgb2 4gaW1wcm92 aW5nIHBhdG llbnQgb3V0 Y29tZXMgYW 5kIGRldmVs b3Bpbmcgbm V3IHRyZWF0 bWVudHMgZm 9yIGV5ZSBk aXNlYXNlcy 4gVGhleSBo YXZlIGEgZG VkaWNhdGVk IFImRCBjZW 50ZXIgYW5k IGNvbGxhYm 9yYXRpb25z IHdpdGggbG VhZGluZyBy ZXNlYXJjaC BpbnN0aXR1 dGlvbnMuID xicj40LiBT dXN0YWluYW JpbGl0eTog U2FudGVuIG lzIGNvbW1p dHRlZCB0by BzdXN0YWlu YWJpbGl0eS BhbmQgZXRo aWNhbCBidX NpbmVzcyBw cmFjdGljZX MuIFRoZXkg aGF2ZSBpbX BsZW1lbnRl ZCBpbml0aW F0aXZlcyB0 byByZWR1Y2 UgdGhlaXIg ZW52aXJvbm 1lbnRhbCBp bXBhY3QgYW 5kIHByb21v dGUgc29jaW FsIHJlc3Bv bnNpYmlsaX R5LCBzdWNo IGFzIHVzaW 5nIGVjby1m cmllbmRseS BtYXRlcmlh bHMgYW5kIH Byb21vdGlu ZyBkaXZlcn NpdHkgYW5k IGluY2x1c2 lvbiB3aXRo aW4gdGhlIG NvbXBhbnku IDxicj41Li BQYXRpZW50 LUNlbnRyaW MgQXBwcm9h Y2g6IFNhbn RlbiBwdXRz IHRoZSBwYX RpZW50IGF0 IHRoZSBjZW 50ZXIgb2Yg ZXZlcnl0aG luZyB0aGV5 IGRvLCB3aX RoIGEgZ29h bCBvZiBpbX Byb3Zpbmcg dGhlIHF1YW xpdHkgb2Yg bGlmZSBmb3 IgdGhvc2Ug YWZmZWN0ZW QgYnkgZXll IGRpc2Vhc2 VzLiBUaGV5 IHN0cml2ZS B0byBsaXN0 ZW4gdG8gcG F0aWVudHMg YW5kIGhlYW x0aGNhcmUg cHJvZmVzc2 lvbmFscyBh bmQgZGV2ZW xvcCBwcm9k dWN0cyB0aG F0IG1lZXQg dGhlaXIgbm VlZHMuIDxi cj42LiBQYX J0bmVyc2hp cCBhbmQgQ2 9sbGFib3Jh dGlvbjogU2 FudGVuIHBh cnRuZXJzIH dpdGggb3Ro ZXIgY29tcG FuaWVzIGFu ZCBvcmdhbm l6YXRpb25z IHRvIGRldm Vsb3AgbmV3 IHRyZWF0bW VudHMgYW5k IGltcHJvdm UgcGF0aWVu dCBjYXJlLi BUaGV5IGFs c28gY29sbG Fib3JhdGUg d2l0aCBwYX RpZW50IG9y Z2FuaXphdG lvbnMgYW5k IGFkdm9jYW N5IGdyb3Vw cyB0byByYW lzZSBhd2Fy ZW5lc3MgYW JvdXQgZXll IGhlYWx0aC BhbmQgc3Vw cG9ydCBwYX RpZW50cy4=
What the company's business model?
Santen Pharmaceutical

πŸ“ˆ Want to read more about Santen Pharmaceutical?

Sign up for free or log in

πŸ™Œ Join now to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" at no cost

VGhlIFNhbn RlbiBQaGFy bWFjZXV0aW NhbCBjb21w YW554oCZcy BidXNpbmVz cyBtb2RlbC Bmb2N1c2Vz IG9uIHJlc2 VhcmNoLCBk ZXZlbG9wbW VudCwgcHJv ZHVjdGlvbi wgYW5kIG1h cmtldGluZy BvZiBwaGFy bWFjZXV0aW NhbHMgYW5k IG1lZGljYW wgZGV2aWNl cyBpbiB0aG Ugb3BodGhh bG1pYyBmaW VsZC4gVGhl aXIgbWFpbi Bwcm9kdWN0 cyBpbmNsdW RlIHByZXNj cmlwdGlvbi BkcnVncywg b3Zlci10aG UtY291bnRl ciBwcm9kdW N0cywgYW5k IG1lZGljYW wgZGV2aWNl cyBmb3IgdH JlYXRtZW50 IG9mIHZhcm lvdXMgZXll IGRpc2Vhc2 VzIGFuZCBj b25kaXRpb2 5zLiBUaGV5 IGFsc28gaG F2ZSBhIHN0 cm9uZyBwcm VzZW5jZSBp biBpbnRlcm 5hdGlvbmFs IG1hcmtldH MgdGhyb3Vn aCBwYXJ0bm Vyc2hpcHMg YW5kIGNvbG xhYm9yYXRp b25zIHdpdG ggb3RoZXIg cGhhcm1hY2 V1dGljYWwg Y29tcGFuaW VzLiBUaGUg Y29tcGFuee KAmXMgYnVz aW5lc3Mgc3 RyYXRlZ3kg aXMgYmFzZW Qgb24gaW5u b3ZhdGlvbi wgcXVhbGl0 eSwgYW5kIG dsb2JhbCBl eHBhbnNpb2 4gdG8gbWVl dCB0aGUgbm VlZHMgb2Yg cGF0aWVudH MgYW5kIGhl YWx0aGNhcm UgcHJvZmVz c2lvbmFscy 4=
Interesting facts about the company
Santen Pharmaceutical

πŸ“ˆ Want to read more about Santen Pharmaceutical?

Sign up for free or log in

πŸ“₯ Get our free eBook now: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvZT Q0aDJFZzFJ VkFZNmYxWW R3Nkwud2Vi cCIgYWx0PS JTYW50ZW4g UGhhcm1hY2 V1dGljYWwi IHRpdGxlPS JTYW50ZW4g UGhhcm1hY2 V1dGljYWwi ICBjbGFzcz 0iaW1nLWZs dWlkIiBoZW lnaHQ9OTAg d2lkdGg9OT AgbG9hZGlu Zz0nbGF6eS cgc3R5bGU9 J2JvcmRlci 1yYWRpdXM6 IDZweDsnPg oKICAgICAg ICAgICAgIC AgICAgICA8 ZGl2IHN0eW xlPSdmbGV4 OiAxOyB0ZX h0LWFsaWdu OiBjZW50ZX I7IG1hcmdp bi1sZWZ0Oi A1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPHAgc3R5 bGU9J2Zvbn Qtc2l6ZTog MjZweDsgY2 9sb3I6ICMz MzM7IG1hcm dpbi1ib3R0 b206IDE1cH g7Jz4KICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIPCfk4gg V2FudCB0by ByZWFkIG1v cmUgYWJvdX QgU2FudGVu IFBoYXJtYW NldXRpY2Fs PwogICAgIC AgICAgICAg ICAgICAgIC AgICA8L3A+ CgogICAgIC AgICAgICAg ICAgICAgIC AgICA8YSBo cmVmPSdpbm RleC5waHA/ cGFnZT1zaW dudXAnIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGJhY2 tncm91bmQt Y29sb3I6IC MwMDdCRkY7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBj b2xvcjogI2 ZmZjsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH ggMjBweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIGJv cmRlci1yYW RpdXM6IDVw eDsKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IHRleHQtZG Vjb3JhdGlv bjogbm9uZT sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG ZvbnQtd2Vp Z2h0OiBib2 xkOwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgbWFyZ2lu LXJpZ2h0Oi AxMHB4Owog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgdHJh bnNpdGlvbj ogYmFja2dy b3VuZC1jb2 xvciAwLjNz IGVhc2U7Jw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgb2 5tb3VzZW92 ZXI9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA1Nm IzIicKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIG9ubW91 c2VvdXQ9J3 RoaXMuc3R5 bGUuYmFja2 dyb3VuZENv bG9yPSIjMD A3QkZGIic+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBT aWduIHVwIG ZvciBmcmVl CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwvYT4K CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDxzcGFu IHN0eWxlPS dtYXJnaW46 IDAgOHB4Oy Bjb2xvcjog IzU1NTsnPm 9yPC9zcGFu PgoKICAgIC AgICAgICAg ICAgICAgIC AgICAgPGEg aHJlZj0naW 5kZXgucGhw P3BhZ2U9bG 9naW4nIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGNvbG 9yOiAjMDA3 QkZGOwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgdGV4dC 1kZWNvcmF0 aW9uOiB1bm RlcmxpbmU7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBm b250LXdlaW dodDogNTAw Oyc+CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICBsb2cgaW 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9hPg oKCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxwIH N0eWxlPSdt YXJnaW4tdG 9wOiAxNXB4 OyBmb250LX NpemU6IDEz cHg7IGZvbn Qtd2VpZ2h0 OiBib2xkOy Bjb2xvcjog I2QzMmYyZj snPgogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Ag8J+ZjCBK b2luIG5vdy B0byBnZXQg PGk+IlRoZS BDaGVja2xp c3QgVmFsdW UgSW52ZXN0 b3Ig4oCUIE EgU21hcnRl ciBXYXkgdG 8gUGljayBT dG9ja3MiPC 9pPiBhdCBu byBjb3N0Ci AgICAgICAg ICAgICAgIC AgICAgICAg IDwvcD4KCi AgICAgICAg ICAgICAgIC AgICAgICAg IDwhLS0KIC AgICAgICAg ICAgICAgIC AgICAgICAg PGRpdiBzdH lsZT0nbWFy Z2luLXRvcD ogMTJweDsg Zm9udC1zaX plOiAxM3B4 OyBjb2xvcj ogIzQ0NDsn PgogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg U2lnbiB1cC Bub3cgYW5k IGdldCBvdX IgZnJlZSBl Qm9vayAKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIDxiPl RoZSBDaGVj a2xpc3QgVm FsdWUgSW52 ZXN0b3Ig4o CUIEEgU21h cnRlciBXYX kgdG8gUGlj ayBTdG9ja3 M8L2I+CiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvZGl2Pgog ICAgICAgIC AgICAgICAg ICAgICAgIC AtLT4KICAg ICAgICAgIC AgICAgICAg ICAgICAgPC EtLQogICAg ICAgICAgIC AgICAgICAg ICAgICA8ZG l2IHN0eWxl PSdtYXJnaW 4tdG9wOiAx NnB4OyBmb2 50LXNpemU6 IDE0cHg7IG NvbG9yOiAj NDQ0OyBmb2 50LWZhbWls eTogLWFwcG xlLXN5c3Rl bSwgQmxpbm tNYWNTeXN0 ZW1Gb250LC BTZWdvZSBV SSwgUm9ib3 RvLCBIZWx2 ZXRpY2EgTm V1ZSwgc2Fu cy1zZXJpZj sgbGluZS1o ZWlnaHQ6ID EuNjsnPgog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgSGF2 ZSB5b3UgaG VhcmQgYWJv dXQgb3VyIH Nob3J0IDxz dHJvbmcgc3 R5bGU9J2Zv bnQtd2VpZ2 h0OiA2MDA7 Jz5EYWlseS BWaWRlbyBO ZXdzbGV0dG VyPC9zdHJv bmc+PwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgPGEgaH JlZj0naHR0 cHM6Ly93d3 cuaW5zaWdo dGZ1bHZhbH VlLmNvbS9u ZXdzbGV0dG VyLnBocCcg dGFyZ2V0PS dfYmxhbmsn IHN0eWxlPS djb2xvcjog IzAwN0JGRj sgdGV4dC1k ZWNvcmF0aW 9uOiBub25l OyBmb250LX dlaWdodDog NTAwOyBtYX JnaW4tbGVm dDogNnB4Oy c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgRmlu ZCBvdXQgbW 9yZQogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgPC9hPgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L2Rpdj4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgLS0+CiAg ICAgICAgIC AgICAgICAg ICAgPC9kaX Y+CiAgICAg ICAgICAgIC AgICA8L2Rp dj4KICAgIC AgICAgICAg PC9kaXY+Ci AgICAgICAg ICAgIAogIC AgICAgIAog ICAgICAgID xzcGFuIGNs YXNzPSdibH VycmVkLXRl eHQnPgogIC AgICAgICAg ICBNUzRnVT JGdWRHIFZ1 SUZCb1lYSn QgWVdObGRY UnBZMiBGc0 lFTnZMaXdn IFRIUmtMaU JpWlcgZGhi aUJwZEhNZy BhSFZ0WW14 bElHIHB2ZF hKdVpYa2cg YVc0Z1NtRn dZVyA0Z1lY TWdZU0IzIG FHOXNaWE5o YkcgVWdaSE oxWjJkcCBj M1FnYVc0Z0 1UIGc1TUN3 Z2RXNWsgWl hJZ2RHaGxJ RyA1aGJXVW dSblZyIGRX aGhjbUVnUz IgbDBZV2Ro ZDJFZyBVMm h2ZEdWdUxq IHhpY2o0eU xpQkogYmlB eE9URTVMQy BCR2RXdDFh R0Z5IFlTQk xhWFJoWjIg RjNZU0JUYU c5MCBaVzRn ZDJGeklHIG x1WTI5eWNH OXkgWVhSbF pDQmhibSBR Z2NtVnVZVz FsIFpDQlRZ VzUwWlcgNG dVR2hoY20x aCBZMlYxZE dsallXIHdn UTI4dUxDQk 0gZEdRdUlG Um9aUyBCam IyMXdZVzU1 IElIZGhjeU JtYjIgTjFj MlZrSUc5dS BJSFJvWlNC d2NtIDlrZF dOMGFXOXUg SUc5bUlHVj VaUyBCa2Nt OXdjeUJoIG JtUWdiM1Jv WlggSWdaWG xsSUdOaCBj bVVnY0hKdl pIIFZqZEhN dVBHSnkgUG pNdUlGUnZa RyBGNUxDQl RZVzUwIFpX NGdhWE1nYj IgNWxJRzlt SUhSbyBaU0 JzWVhKblpY IE4wSUVwaG NHRnUgWlhO bElHTnZiWC BCaGJtbGxj eUIwIGFHRj BJSE53Wlcg TnBZV3hwZW 1WeiBJR2x1 SUhSb1pTIE JrWlhabGJH OXcgYldWdW RDd2djSCBK dlpIVmpkR2 x2IGJpd2dZ VzVrSUcgMW hjbXRsZEds dSBaeUJ2Wm lCdmNHIGgw YUdGc2JXbG ogSUhCb1lY SnRZVyBObG RYUnBZMkZz IGN5d2diV1 ZrYVcgTmhi Q0JrWlhacC BZMlZ6TENC aGJtIFFnYj NabGNpMTAg YUdVdFkyOT FibiBSbGNp QmxlV1VnIF kyRnlaU0J3 Y20gOWtkV0 4wY3k0OCBZ bkkrTkM0Z1 ZHIGhsSUdO dmJYQmggYm 5rZ2FHRnpJ RyBFZ2MzUn liMjVuIElH bHVkR1Z5Ym 0gRjBhVzl1 WVd3ZyBjSE psYzJWdVky IFVzSUhkcG RHZ2cgYjNC bGNtRjBhVy A5dWN5QnBi aUJ2IGRtVn lJRFl3SUcg TnZkVzUwY2 1sbCBjeUJo Ym1RZ2NtIF ZuYVc5dWN5 QjMgYjNKc1 pIZHBaRyBV dVBHSnlQal V1IElGTmhi blJsYnUgS0 FtWE1nWTI5 eSBjRzl5WV hSbElHIDFw YzNOcGIyNG cgYVhNZ2RH OGdZMiA5dW RISnBZblYw IFpTQjBieU IwYUcgVWdk MlZzYkMxaS BaV2x1WnlC dlppIEJ3WV hScFpXNTAg Y3lCaWVTQn djbSA5MmFX UnBibWNnIG FXNXViM1po ZEcgbDJaU3 dnYUdsbiBh QzF4ZFdGc2 FYIFI1SUhC eWIyUjEgWT NSeklHRnVa QyBCelpYSj JhV05sIGN5 QnBiaUIwYU cgVWdabWxs YkdRZyBiMl lnYjNCb2RH IGhoYkcxdm JHOW4gZVM0 OFluSStOaS A0Z1UyRnVk R1Z1IElHaG hjeUJoSUgg TjBjbTl1Wn lCaiBiMjF0 YVhSdFpXID UwSUhSdklI SmwgYzJWaG NtTm9JRyBG dVpDQmtaWF psIGJHOXdi V1Z1ZEMgd2 dhVzUyWlhO MCBhVzVuSU c5MlpYIEln TWpBbElHOW 0gSUdsMGN5 QnlaWCBabG JuVmxJR2x1 IElIUm9aU0 JrWlggWmxi Rzl3YldWdS BkQ0J2WmlC dVpYIGNnY0 hKdlpIVmog ZEhNZ1lXNW tJSCBSbFky aHViMnh2IF oybGxjeTQ4 WW4gSStOeT RnVkdobCBJ R052YlhCaG JuIGtnYVhN Z2EyNXYgZD I0Z1ptOXlJ RyBsMGN5Qm xlSEJsIGNu UnBjMlVnYV cgNGdkR2hs SUhSeSBaV0 YwYldWdWRD IEJ2WmlCbm JHRjEgWTI5 dFlTd2daSC BKNUlHVjVa U0JrIGFYTm xZWE5sTEMg QmhibVFnYj NSbyBaWEln WlhsbElHIF JwYzI5eVpH VnkgY3k0Z1 NYUWdZVyB4 emJ5QnZabV psIGNuTWdZ U0J5WVcgNW 5aU0J2WmlC eiBkWEpuYV dOaGJDIEJ3 Y205a2RXTj AgY3lCbWIz SWdZMiBGMF lYSmhZM1Fn IFlXNWtJR2 RzWVggVmpi MjFoSUhOMS BjbWRsY21s bGN5IDQ4WW 5JK09DNGcg VTJGdWRHVn VJRyBoaGN5 QnlaV05sIG FYWmxaQ0J1 ZFcgMWxjbT kxY3lCaCBk MkZ5WkhNZ1 lXIDVrSUdG alkyOXMgWV dSbGN5Qm1i MyBJZ2FYUn pJR052IGJX MXBkRzFsYm 4gUWdkRzhn WTI5eSBjRz l5WVhSbElI IE52WTJsaG JDQnkgWlhO d2IyNXphVy BKcGJHbDBl U3dnIGMzVn pkR0ZwYm0g RmlhV3hwZE hrcyBJR0Z1 WkNCbGRHIG hwWTJGc0lH SjEgYzJsdV pYTnpJSCBC eVlXTjBhV0 5sIGN5NDhZ bkkrT1MgNG dTVzRnWVdS ayBhWFJwYj I0Z2RHIDhn YVhSeklIQm 8gWVhKdFlX TmxkWCBScF kyRnNJSEJ5 IGIyUjFZM1 J6TEMgQlRZ VzUwWlc0Zy BZV3h6YnlC dlptIFpsY2 5NZ1lTQnkg WVc1blpTQn ZaaSBCdWIy NHRjR2hoIG NtMWhZMlYx ZEcgbGpZV3 dnY0hKdiBa SFZqZEhNc0 lHIGx1WTJ4 MVpHbHUgWn lCamIyNTBZ VyBOMElHeG xibk5sIGN5 d2daWGxsSU cgTmhjbVVn YzNWdyBjR3 hsYldWdWRI IE1zSUdGdV pDQnQgWldS cFkyRnNJRy BSbGRtbGpa WE11IFBHSn lQakV3TGkg QkVaWE53YV hSbCBJR2ww Y3lCbmJHID lpWVd3Z2Mz VmogWTJWem N5d2dVMiBG dWRHVnVJSE psIGJXRnBi bk1nWVMgQm 1ZVzFwYkhr dCBjblZ1SU dOdmJYIEJo Ym5rZ2QybD AgYUNCMGFH VWdabSA5MW NuUm9JR0Z1 IFpDQm1hV1 owYUMgQm5a VzVsY21GMC BhVzl1Y3lC dlppIEIwYU dVZ2IzSnAg WjJsdVlXd2 dabSA5MWJt Umxjbk1nIG MzUnBiR3dn YVcgNTJiMn gyWldRZyBh VzRnZEdobE lHIEoxYzJs dVpYTnogTG lCVWFHbHpJ RyBoaGN5Qm 9aV3h3IFpX UWdkRzhnYl cgRnBiblJo YVc0ZyBZU0 J6ZEhKdmJt IGNnYzJWdW MyVWcgYjJZ Z2RISmhaRy BsMGFXOXVM Q0JqIGIyMX RhWFJ0Wlcg NTBJSFJ2SU dWNCBZMlZz YkdWdVkyIF VzSUdGdVpD QmsgWldScF kyRjBhVyA5 dUlIUnZJSE JoIGRHbGxi blFnWTIgRn laUzQ9CiAg ICAgICAgPC 9zcGFuPgog ICAgICAgIA ogICAgICAg IA==
See Company Q&A
Santen Pharmaceutical

πŸ“Š Get full analytics about Santen Pharmaceutical

Sign up for free or log in

πŸ’‘ Learn smarter stock picks with "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

© 2024 - 2025 InsightfulValue.com. All rights reserved. Newsletter
Legal